Takeda Pharmaceutical Co Ltd 2024 SR
The report highlights Takeda's ESG performance for the fiscal year ended March 31, 2024, showcasing a 53% reduction in Scope 1 and 2 greenhouse gas emissions relative to a 2016 baseline. The company achieved 100% timely disclosure of clinical trial results and maintained a 99.1% on-time-in-full product dispatch rate. Diversity initiatives resulted in a workforce comprising 52% women, with 41% in top management positions. Additionally, 56% of Scope 3 emissions now come from suppliers committed to science-based climate targets, and the company successfully diverted 78% of its waste from landfills.
Company: Takeda Pharmaceutical Co Ltd
Sector: Manufacturing
Country: Japan
Year: 2024
Type: SR
Pages: 79
Back to company
Takeda Pharmaceutical Co Ltd
ESG Databook
The report highlights Takeda's ESG performance for the fiscal year ended March 31, 2024, showcasing a 53% reduction in Scope 1 and 2 greenhouse gas emissions relative to a 2016 baseline. The company achieved 100% timely disclosure of clinical trial results and maintained a 99.1% on-time-in-full product dispatch rate. Diversity initiatives resulted in a workforce comprising 52% women, with 41% in top management positions. Additionally, 56% of Scope 3 emissions now come from suppliers committed to science-based climate targets, and the company successfully diverted 78% of its waste from landfills.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2023
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women in Management
Workplace Fatalities
Employees